soul trial oral semaglutide cardiovascular outcomes 2025 align more closely with attained dose than achieved weight loss Semaglutide Cardiovascular Outcomes Trial -

Are there potential health benefits of semaglutide for teens

According to NICE guidance (TA875 and TA664), GLP-1 receptor agonists for weight management are typically initiated and supervised by specialist weight management services, with treatment duration limits (up to 2 years for semaglutide) and specific continuation criteria

Patients with a history of chronic pancreatitis, pancreatic cancer, or other significant pancreatic disorders may not be suitable candidates for this therapy

Setoyama D, Lee HY, Moon JS, Tian J, Kang YE, Lee JH, et al

Weight Watchers Med+ helps make accessing a weight-loss medication convenient and easy, if you qualify, through a brand you know and trust

GLP-1 medications drive changes in two distinct ways: through the direct effects of the drug on your digestive system, and through the body composition changes that come with significant weight loss